首页 > 最新文献

Research and Reports in Urology最新文献

英文 中文
Administration of Caesalpinia bonduc Seed Extracts Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia (BPH) in Male Wistar Rats 给药荆芥籽提取物改善雄性Wistar大鼠睾丸激素诱导的良性前列腺增生(BPH)
IF 1.6 Q2 UROLOGY & NEPHROLOGY Pub Date : 2022-05-01 DOI: 10.2147/RRU.S365598
Shan Sasidharan, Srinivasakumar Kp, A. Bhaumik, Sreemoy Kanti Das, Hareebndran Nair J
Introduction Benign prostatic hyperplasia (BPH) is a major chronic disease affecting men, and the therapeutic agents currently used to manage it have significant side effects. As a result, an alternative medicine with improved therapeutic properties with no side effects is desperately needed. The current investigation aims to study whether the Caesalpinia bonduc seed extracts (ethanolic-A, hydroalcoholic-B, and aqueous-C) have inhibitory potential on testosterone propionate (TP)-induced BPH in Wistar rats. Methods Wistar rats (male) were randomly allocated to one of five groups: control, BPH (TP-3 mg/kg, subcutaneously daily), low dose (TP + C. bonduc seed extracts – 200 mg/kg body weight), high dose (TP + C. bonduc seed extracts – 400 mg/kg body weight), and standard drug (TP + finasteride – 10 mg/kg body weight). At the end of drug treatment, the rats were sacrificed and their serum and prostates were taken for biochemical and histological studies. Results C. bonduc seed extracts treatment significantly decreased prostate weight and prostatic index in rats with TP-induced BPH. The seed extracts exhibited a potent inhibitory effect on dihydrotestosterone (DHT) in serum and prostate. In addition, the PSA level in the serum showed a noteworthy decrease in comparison with the BPH group. Histopathological examination also indicated that extracts improved the tissue morphology of the prostate significantly. Out of three extracts tested, ethanolic and hydroalcoholic extract recorded significant effect. Finally, liquid chromatography quadrupole time-of-flight mass spectrometry (LC/MS-QTOF) analysis showed that the major compounds present in the extracts were tocopherols, fucosterol, linoleic acid, β-amyrin, β-sitosterol, campesterol, cassane furanoditerpene, norcassane furanoditerpene and other diterpenes. Conclusion Thus, C. bonduc seed extracts could be a potential source for the formulation of new drug for managing BPH. To the best of our knowledge, this is the first scientific animal investigation into the use of C. bonduc seed extract for the management of BPH.
引言良性前列腺增生(BPH)是一种影响男性的主要慢性疾病,目前用于治疗它的药物有显著的副作用。因此,迫切需要一种具有改善治疗性能且无副作用的替代药物。本研究的目的是研究金合欢种子提取物(乙醇-A、乙醇-B和水-C)是否对丙酸睾酮(TP)诱导的Wistar大鼠前列腺增生具有抑制作用。方法Wistar大鼠(雄性)随机分为五组:对照组、前列腺增生组(TP-3 mg/kg,每天皮下注射)、低剂量组(TP+C.bonduc种子提取物–200 mg/kg体重)、高剂量组(TP+C.bonduk种子提取物–400 mg/kg体重)和标准药物组(TP+非那雄胺–10 mg/kg体重)。药物治疗结束时,处死大鼠,取其血清和前列腺进行生化和组织学研究。结果邦杜克种子提取物治疗能显著降低TP诱导的BPH大鼠前列腺重量和前列腺指数。种子提取物对血清和前列腺中的二氢睾酮(DHT)具有强大的抑制作用。此外,与前列腺增生组相比,血清中的PSA水平显著下降。组织病理学检查还表明,提取物显著改善了前列腺的组织形态。在测试的三种提取物中,乙醇和水醇提取物的效果显著。最后,液相色谱-四极杆飞行时间质谱(LC/MS-QTOF)分析表明,提取物中存在的主要化合物为生育酚、岩藻甾醇、亚油酸、β-胰淀素、β-谷甾醇、樟脑酯醇、呋喃二萜、norcassane呋喃二萜和其他二萜。结论邦杜克种子提取物是研制治疗前列腺增生新药的潜在来源。据我们所知,这是首次对邦杜克C.bonduc种子提取物用于BPH治疗的科学动物调查。
{"title":"Administration of Caesalpinia bonduc Seed Extracts Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia (BPH) in Male Wistar Rats","authors":"Shan Sasidharan, Srinivasakumar Kp, A. Bhaumik, Sreemoy Kanti Das, Hareebndran Nair J","doi":"10.2147/RRU.S365598","DOIUrl":"https://doi.org/10.2147/RRU.S365598","url":null,"abstract":"Introduction Benign prostatic hyperplasia (BPH) is a major chronic disease affecting men, and the therapeutic agents currently used to manage it have significant side effects. As a result, an alternative medicine with improved therapeutic properties with no side effects is desperately needed. The current investigation aims to study whether the Caesalpinia bonduc seed extracts (ethanolic-A, hydroalcoholic-B, and aqueous-C) have inhibitory potential on testosterone propionate (TP)-induced BPH in Wistar rats. Methods Wistar rats (male) were randomly allocated to one of five groups: control, BPH (TP-3 mg/kg, subcutaneously daily), low dose (TP + C. bonduc seed extracts – 200 mg/kg body weight), high dose (TP + C. bonduc seed extracts – 400 mg/kg body weight), and standard drug (TP + finasteride – 10 mg/kg body weight). At the end of drug treatment, the rats were sacrificed and their serum and prostates were taken for biochemical and histological studies. Results C. bonduc seed extracts treatment significantly decreased prostate weight and prostatic index in rats with TP-induced BPH. The seed extracts exhibited a potent inhibitory effect on dihydrotestosterone (DHT) in serum and prostate. In addition, the PSA level in the serum showed a noteworthy decrease in comparison with the BPH group. Histopathological examination also indicated that extracts improved the tissue morphology of the prostate significantly. Out of three extracts tested, ethanolic and hydroalcoholic extract recorded significant effect. Finally, liquid chromatography quadrupole time-of-flight mass spectrometry (LC/MS-QTOF) analysis showed that the major compounds present in the extracts were tocopherols, fucosterol, linoleic acid, β-amyrin, β-sitosterol, campesterol, cassane furanoditerpene, norcassane furanoditerpene and other diterpenes. Conclusion Thus, C. bonduc seed extracts could be a potential source for the formulation of new drug for managing BPH. To the best of our knowledge, this is the first scientific animal investigation into the use of C. bonduc seed extract for the management of BPH.","PeriodicalId":21008,"journal":{"name":"Research and Reports in Urology","volume":"14 1","pages":"225 - 239"},"PeriodicalIF":1.6,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42050087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
A Drug-Coated Balloon Treatment for Urethral Stricture Disease: Three-Year Results from the ROBUST I Study 尿道狭窄疾病的药物包被球囊治疗:鲁棒I研究的三年结果
IF 1.6 Q2 UROLOGY & NEPHROLOGY Pub Date : 2022-05-01 DOI: 10.2147/RRU.S359872
R. Virasoro, J. DeLong, R. Estrella, M. Pichardo, R. Rodriguez Lay, G. Espino, S. Elliott
Introduction Endoscopic management of male anterior urethral stricture disease is common; however, repeat treatment is associated with high recurrence rates. Here, we report the 3-year results of the ROBUST I trial, which evaluated the safety and efficacy of the Optilume® drug coated balloon (DCB) in men with recurrent urethral strictures. Methods Adult men with recurrent bulbar urethral strictures ≤2 cm in length and 1–4 prior endoscopic interventions were treated with the Optilume DCB. Functional success was defined as ≥50% reduction in International Prostate Symptom Score (IPSS) without need for retreatment. Other outcomes included quality of life, maximum flow rate, post-void residual urine volume, erectile function, and freedom from repeat intervention. Results Of the 53 enrolled and treated men, 33 completed the 3-year visit, with 10 patients experiencing clinical failures at previous visits, giving a total of 43 subjects evaluable for the functional success endpoint. Functional success was achieved in 67% (29/43) and freedom from retreatment in 77% (33/43). Average IPSS improved from 25.2 at baseline to 5.5 at 3 years (p<0.0001). Significant improvements were observed in quality of life, flow rate, and post-void residual urine volume. Erectile function was not affected by treatment. Device-related adverse events were mild or moderate in nature and resolved quickly after onset. There were no serious treatment-related adverse events. Conclusion Symptomatic improvement after treatment with the Optilume DCB was maintained through 3 years in a population highly susceptible to recurrent urethral stricture disease. This minimally invasive therapy is safe with no negative impact on sexual function.
男性前尿道狭窄的内镜治疗是常见的;然而,重复治疗与高复发率相关。在此,我们报告了ROBUST I试验的3年结果,该试验评估了Optilume®药物涂层球囊(DCB)治疗复发性尿道狭窄男性的安全性和有效性。方法采用Optilume DCB治疗长度≤2cm的复发性球根性尿道狭窄成年男性,并进行1-4次内窥镜介入治疗。功能性成功定义为国际前列腺症状评分(IPSS)降低≥50%,无需再治疗。其他结果包括生活质量、最大流速、排尿后残余尿量、勃起功能和免于重复干预。结果在53名入选和接受治疗的男性中,33人完成了3年的访视,其中10名患者在之前的访视中出现了临床失败,共有43名受试者可评估功能成功终点。67%(29/43)获得功能性成功,77%(33/43)免于再治疗。平均IPSS从基线时的25.2改善到3年时的5.5(p<0.0001)。在生活质量、流速和排尿后残余尿量方面观察到显著改善。治疗未影响勃起功能。器械相关不良事件性质为轻度或中度,发病后迅速缓解。没有严重的治疗相关不良事件。结论Optilume DCB治疗复发性尿道狭窄患者后,症状改善持续3年。这种微创治疗是安全的,对性功能没有负面影响。
{"title":"A Drug-Coated Balloon Treatment for Urethral Stricture Disease: Three-Year Results from the ROBUST I Study","authors":"R. Virasoro, J. DeLong, R. Estrella, M. Pichardo, R. Rodriguez Lay, G. Espino, S. Elliott","doi":"10.2147/RRU.S359872","DOIUrl":"https://doi.org/10.2147/RRU.S359872","url":null,"abstract":"Introduction Endoscopic management of male anterior urethral stricture disease is common; however, repeat treatment is associated with high recurrence rates. Here, we report the 3-year results of the ROBUST I trial, which evaluated the safety and efficacy of the Optilume® drug coated balloon (DCB) in men with recurrent urethral strictures. Methods Adult men with recurrent bulbar urethral strictures ≤2 cm in length and 1–4 prior endoscopic interventions were treated with the Optilume DCB. Functional success was defined as ≥50% reduction in International Prostate Symptom Score (IPSS) without need for retreatment. Other outcomes included quality of life, maximum flow rate, post-void residual urine volume, erectile function, and freedom from repeat intervention. Results Of the 53 enrolled and treated men, 33 completed the 3-year visit, with 10 patients experiencing clinical failures at previous visits, giving a total of 43 subjects evaluable for the functional success endpoint. Functional success was achieved in 67% (29/43) and freedom from retreatment in 77% (33/43). Average IPSS improved from 25.2 at baseline to 5.5 at 3 years (p<0.0001). Significant improvements were observed in quality of life, flow rate, and post-void residual urine volume. Erectile function was not affected by treatment. Device-related adverse events were mild or moderate in nature and resolved quickly after onset. There were no serious treatment-related adverse events. Conclusion Symptomatic improvement after treatment with the Optilume DCB was maintained through 3 years in a population highly susceptible to recurrent urethral stricture disease. This minimally invasive therapy is safe with no negative impact on sexual function.","PeriodicalId":21008,"journal":{"name":"Research and Reports in Urology","volume":"14 1","pages":"177 - 183"},"PeriodicalIF":1.6,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43157637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
A Novel Risk Score (P-score) Based on a Three-Gene Signature, for Estimating the Risk of Prostate Cancer-Specific Mortality 一种新的基于三基因特征的风险评分(P评分),用于估计前列腺癌特异性死亡率的风险
IF 1.6 Q2 UROLOGY & NEPHROLOGY Pub Date : 2022-05-01 DOI: 10.2147/RRU.S358169
F. Söderdahl, Lidi Xu, J. Bring, M. Häggman
Purpose To develop and validate a risk score (P-score) algorithm which includes previously described three-gene signature and clinicopathological parameters to predict the risk of death from prostate cancer (PCa) in a retrospective cohort. Patients and Methods A total of 591 PCa patients diagnosed between 2003 and 2008 in Stockholm, Sweden, with a median clinical follow-up time of 7.6 years (1–11 years) were included in this study. Expression of a three-gene signature (IGFBP3, F3, VGLL3) was measured in formalin-fixed paraffin-embedded material from diagnostic core needle biopsies (CNB) of these patients. A point-based scoring system based on a Fine-Gray competing risk model was used to establish the P-score based on the three-gene signature combined with PSA value, Gleason score and tumor stage at diagnosis. The endpoint was PCa-specific mortality, while other causes of death were treated as a competing risk. Out of the 591 patients, 315 patients (estimation cohort) were selected to develop the P-score. The P-score was subsequently validated in an independent validation cohort of 276 patients. Results The P-score was established ranging from the integers 0 to 15. Each one-unit increase was associated with a hazard ratio of 1.39 (95% confidence interval: 1.27–1.51, p < 0.001). The P-score was validated and performed better in predicting PCa-specific mortality than both D’Amico (0.76 vs 0.70) and NCCN (0.76 vs 0.71) by using the concordance index for competing risk. Similar improvement patterns are shown by time-dependent area under the curve. As demonstrated by cumulative incidence function, both P-score and gene signature stratified PCa patients into significantly different risk groups. Conclusion We developed the P-score, a risk stratification system for newly diagnosed PCa patients by integrating a three-gene signature measured in CNB tissue. The P-score could provide valuable decision support to distinguish PCa patients with favorable and unfavorable outcomes and hence improve treatment decisions.
目的:在回顾性队列中,开发并验证一种风险评分(P-score)算法,该算法包括先前描述的三基因特征和临床病理参数,以预测前列腺癌(PCa)的死亡风险。患者和方法本研究共纳入2003 - 2008年在瑞典斯德哥尔摩诊断的591例PCa患者,临床随访时间中位数为7.6年(1-11年)。在这些患者的诊断芯针活检(CNB)中检测福尔马林固定石蜡包埋材料中三个基因特征(IGFBP3, F3, VGLL3)的表达。采用基于Fine-Gray竞争风险模型的积分评分系统,结合PSA值、Gleason评分和诊断时肿瘤分期,建立基于三基因特征的p评分。终点是前列腺癌特异性死亡率,而其他死亡原因被视为竞争风险。在591例患者中,选择315例患者(估计队列)进行p评分。随后在276例患者的独立验证队列中验证了p评分。结果建立的p评分范围为0 ~ 15。每增加一个单位,风险比为1.39(95%可信区间:1.27-1.51,p < 0.001)。通过竞争风险的一致性指数,p -评分在预测前列腺癌特异性死亡率方面优于D 'Amico (0.76 vs 0.70)和NCCN (0.76 vs 0.71)。曲线下随时间变化的面积显示了类似的改进模式。累积发生率函数表明,P-score和基因标记将PCa患者分层为明显不同的风险组。我们通过整合CNB组织中测量的三个基因标记,开发了新诊断的PCa患者的风险分层系统P-score。p -评分可以提供有价值的决策支持,以区分前列腺癌患者的有利和不利的结果,从而改善治疗决策。
{"title":"A Novel Risk Score (P-score) Based on a Three-Gene Signature, for Estimating the Risk of Prostate Cancer-Specific Mortality","authors":"F. Söderdahl, Lidi Xu, J. Bring, M. Häggman","doi":"10.2147/RRU.S358169","DOIUrl":"https://doi.org/10.2147/RRU.S358169","url":null,"abstract":"Purpose To develop and validate a risk score (P-score) algorithm which includes previously described three-gene signature and clinicopathological parameters to predict the risk of death from prostate cancer (PCa) in a retrospective cohort. Patients and Methods A total of 591 PCa patients diagnosed between 2003 and 2008 in Stockholm, Sweden, with a median clinical follow-up time of 7.6 years (1–11 years) were included in this study. Expression of a three-gene signature (IGFBP3, F3, VGLL3) was measured in formalin-fixed paraffin-embedded material from diagnostic core needle biopsies (CNB) of these patients. A point-based scoring system based on a Fine-Gray competing risk model was used to establish the P-score based on the three-gene signature combined with PSA value, Gleason score and tumor stage at diagnosis. The endpoint was PCa-specific mortality, while other causes of death were treated as a competing risk. Out of the 591 patients, 315 patients (estimation cohort) were selected to develop the P-score. The P-score was subsequently validated in an independent validation cohort of 276 patients. Results The P-score was established ranging from the integers 0 to 15. Each one-unit increase was associated with a hazard ratio of 1.39 (95% confidence interval: 1.27–1.51, p < 0.001). The P-score was validated and performed better in predicting PCa-specific mortality than both D’Amico (0.76 vs 0.70) and NCCN (0.76 vs 0.71) by using the concordance index for competing risk. Similar improvement patterns are shown by time-dependent area under the curve. As demonstrated by cumulative incidence function, both P-score and gene signature stratified PCa patients into significantly different risk groups. Conclusion We developed the P-score, a risk stratification system for newly diagnosed PCa patients by integrating a three-gene signature measured in CNB tissue. The P-score could provide valuable decision support to distinguish PCa patients with favorable and unfavorable outcomes and hence improve treatment decisions.","PeriodicalId":21008,"journal":{"name":"Research and Reports in Urology","volume":"14 1","pages":"203 - 217"},"PeriodicalIF":1.6,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43563202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Use of Temporary Membrane-Covered Self-Expandable Metallic Stent – UVENTATM for Treatment of Recurrent Bulbar Urethral Stricture 临时膜覆盖自扩张金属支架UVENTATM治疗复发性球尿道狭窄
IF 1.6 Q2 UROLOGY & NEPHROLOGY Pub Date : 2022-05-01 DOI: 10.2147/RRU.S363557
Ibrahim Alnadhari, Nabil N. Moohialdin, V. Sampige, O. Ali, Osama Abdeljaleel, M. Salah, O. Sedigh, A. Shamsodini, A. Al-Ansari
Introduction Recurrent urethral stricture is a real challenge. Interestingly use of temporary double layered self-expanding nitinol urethral stent with polytetrafluoroethylene (PTFE) membrane coating (UventaTM, Taewoong Medical, South Korea) has been recently reported with promising short-term results in recurrent urethral stricture. However most of the reported studies are published as abstracts of either case reports or case series of miniscule numbers. The aim of our study is to evaluate the outcome of this temporary urethral stent in patients with recurrent urethral stricture after urethroplasty as well as after multiple visual internal urethrotomy. Materials and Methods In this retrospective study, 22 patients had placement of double-layered self-expanding stent with PTFE membrane coating (Uventa, Taewoong Medical) for recurrent bulbar strictures. The present study included cases between 2017 and 2020. The stricture in each patient were evaluated with Uroflowmetry and ascending urethrography. The data of demographic and clinical characteristics included age, aetiology, location and length of stricture, along with maximum urinary flow rate (Qmax), number of previous interventions, and stent-related complications. Results The overall clinical success was achieved in 13/22 (59.1%) of patients at a median follow-up of 17 months (range 2–44). The mean maximum urine flow rates were 7.07 ± 3.55mL/sec, 23.50 ± 10.41mL/sec, 21.41± 15.55 mL/sec, 14.88 ± 9.77 and 17.63 ± 12.28 mL/sec before, while stent in place, at 3 months, 6 months and 12 months after the procedure, respectively. Conclusion In our study, the success rate of temporary urethral stent placement has remained at 59.1% at a median follow-up of 17 months. We conclude that further randomized controlled studies with long-term follow up are required to fully evaluate the outcome.
引言复发性尿道狭窄是一个真正的挑战。有趣的是,最近有报道称,使用具有聚四氟乙烯(PTFE)膜涂层的临时双层自膨胀镍钛诺尿道支架(UventaTM,Taewoong Medical,South Korea)治疗复发性尿道狭窄具有良好的短期效果。然而,大多数报道的研究都是以病例报告或微小数字病例系列的摘要形式发表的。我们研究的目的是评估这种临时尿道支架在尿道成形术后和多次尿道内切开术后复发性尿道狭窄患者中的效果。材料和方法在这项回顾性研究中,22名患者因复发性延髓狭窄而放置了双层PTFE膜自膨胀支架(Uventa,Taewoong Medical)。本研究包括2017年至2020年间的病例。每例患者的狭窄情况均采用尿流量测定法和上行尿道造影术进行评估。人口统计学和临床特征的数据包括年龄、病因、狭窄的位置和长度,以及最大尿流量(Qmax)、既往干预次数和支架相关并发症。结果在中位随访17个月(2-4 4个月)时,13/22(59.1%)的患者获得了总体临床成功。支架置入前、术后3个月、6个月和12个月的平均最大尿流量分别为7.07±3.55mL/s、23.50±10.41mL/s、21.41±15.55mL/s、14.88±9.77和17.63±12.28mL/s。结论在我们的研究中,在中位随访17个月时,临时尿道支架置入的成功率保持在59.1%。我们的结论是,需要进一步的随机对照研究和长期随访来全面评估结果。
{"title":"Use of Temporary Membrane-Covered Self-Expandable Metallic Stent – UVENTATM for Treatment of Recurrent Bulbar Urethral Stricture","authors":"Ibrahim Alnadhari, Nabil N. Moohialdin, V. Sampige, O. Ali, Osama Abdeljaleel, M. Salah, O. Sedigh, A. Shamsodini, A. Al-Ansari","doi":"10.2147/RRU.S363557","DOIUrl":"https://doi.org/10.2147/RRU.S363557","url":null,"abstract":"Introduction Recurrent urethral stricture is a real challenge. Interestingly use of temporary double layered self-expanding nitinol urethral stent with polytetrafluoroethylene (PTFE) membrane coating (UventaTM, Taewoong Medical, South Korea) has been recently reported with promising short-term results in recurrent urethral stricture. However most of the reported studies are published as abstracts of either case reports or case series of miniscule numbers. The aim of our study is to evaluate the outcome of this temporary urethral stent in patients with recurrent urethral stricture after urethroplasty as well as after multiple visual internal urethrotomy. Materials and Methods In this retrospective study, 22 patients had placement of double-layered self-expanding stent with PTFE membrane coating (Uventa, Taewoong Medical) for recurrent bulbar strictures. The present study included cases between 2017 and 2020. The stricture in each patient were evaluated with Uroflowmetry and ascending urethrography. The data of demographic and clinical characteristics included age, aetiology, location and length of stricture, along with maximum urinary flow rate (Qmax), number of previous interventions, and stent-related complications. Results The overall clinical success was achieved in 13/22 (59.1%) of patients at a median follow-up of 17 months (range 2–44). The mean maximum urine flow rates were 7.07 ± 3.55mL/sec, 23.50 ± 10.41mL/sec, 21.41± 15.55 mL/sec, 14.88 ± 9.77 and 17.63 ± 12.28 mL/sec before, while stent in place, at 3 months, 6 months and 12 months after the procedure, respectively. Conclusion In our study, the success rate of temporary urethral stent placement has remained at 59.1% at a median follow-up of 17 months. We conclude that further randomized controlled studies with long-term follow up are required to fully evaluate the outcome.","PeriodicalId":21008,"journal":{"name":"Research and Reports in Urology","volume":"14 1","pages":"219 - 223"},"PeriodicalIF":1.6,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42058315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Imaging and Chemical Analysis of External and Internal Ureteral Stent Encrustation. 输尿管内外支架包膜的影像学和化学分析
IF 2 Q2 UROLOGY & NEPHROLOGY Pub Date : 2022-04-23 eCollection Date: 2022-01-01 DOI: 10.2147/RRU.S364336
Tal Amitay-Rosen, Ishai Dror, Yaniv Shilo, Brian Berkowitz

Introduction: Ureteral stents are effective in alleviating flow disruptions in the urinary tract, whether due to ureteral stones, strictures or extrinsic ureteral obstruction. However, significant stent encrustation on the external and/or internal stent lumen walls can occur, which may interfere with stent functioning and/or removal. Currently, there is only limited, generally qualitative, information on the distribution, mineral structure, and chemical content of these deposits, particularly in terms of stent lumen encrustation.

Objective: To quantify, in an initial investigation, external and internal encrustation in representative, intact ureteral stents. The study investigates possible correlations between patterns of external and internal encrustation, determines mineral structure and chemical composition, and examines the potential for stent lumen obstruction even in the absence of external stent wall encrustation.

Study design: High-resolution, laboratory micro-computed tomography (micro-CT) was used to non-destructively image external and internal stent encrustation in four representative stents. X-ray diffractometry (XRD) and scanning electron microscopy-energy dispersive x-ray spectroscopy (SEM-EDS) enabled parallel analysis of mineral structure and chemical content of samples collected from external and internal encrusted material along the distal, proximal and mid-ureteral stent regions.

Results: Extensive stent lumen encrustation can occur within any region of a stent, with only incidental or minor external encrustation, along the entire length of the stent. External and internal encrusted materials in a given stent are generally similar, consisting of a combination of amorphous (mostly organic) and crystalline mineral deposits.

Conclusion: Micro-CT demonstrates that significant stent lumen encrustation can occur, which can lead to partial or full stent lumen occlusion, even when the exterior stent wall is essentially free of encrusted material.

引言输尿管支架可有效缓解因输尿管结石、狭窄或外源性输尿管梗阻引起的尿路血流中断。然而,支架管腔外壁和/或内壁上可能会出现明显的支架结垢,这可能会干扰支架的功能和/或移除。目前,关于这些沉积物的分布、矿物结构和化学含量,特别是支架管腔结垢的信息有限,通常是定性的。目的在初步研究中,量化具有代表性的完整输尿管支架的内外部结垢。该研究调查了外部和内部结垢模式之间的可能相关性,确定了矿物结构和化学成分,并检查了即使在没有外部支架壁结垢的情况下支架管腔阻塞的可能性。研究设计高分辨率实验室微型计算机断层扫描(micro-CT)用于对四种具有代表性的支架的内外部支架结垢进行无损成像。X射线衍射仪(XRD)和扫描电子显微镜-能量色散X射线光谱法(SEM-EDS)能够并行分析从输尿管支架远端、近端和中段的外部和内部包裹材料中收集的样品的矿物结构和化学含量。结果在支架的任何区域都可能发生广泛的支架管腔结垢,在支架的整个长度上只有偶然或轻微的外部结垢。给定支架中的外部和内部包覆材料通常相似,由非晶(主要是有机)和结晶矿物沉积物的组合组成。结论显微CT显示,即使支架外壁基本上没有结垢物质,也会发生明显的支架管腔结垢,从而导致部分或全部支架管腔堵塞。
{"title":"Imaging and Chemical Analysis of External and Internal Ureteral Stent Encrustation.","authors":"Tal Amitay-Rosen, Ishai Dror, Yaniv Shilo, Brian Berkowitz","doi":"10.2147/RRU.S364336","DOIUrl":"10.2147/RRU.S364336","url":null,"abstract":"<p><strong>Introduction: </strong>Ureteral stents are effective in alleviating flow disruptions in the urinary tract, whether due to ureteral stones, strictures or extrinsic ureteral obstruction. However, significant stent encrustation on the external and/or internal stent lumen walls can occur, which may interfere with stent functioning and/or removal. Currently, there is only limited, generally qualitative, information on the distribution, mineral structure, and chemical content of these deposits, particularly in terms of stent lumen encrustation.</p><p><strong>Objective: </strong>To quantify, in an initial investigation, external and internal encrustation in representative, intact ureteral stents. The study investigates possible correlations between patterns of external and internal encrustation, determines mineral structure and chemical composition, and examines the potential for stent lumen obstruction even in the absence of external stent wall encrustation.</p><p><strong>Study design: </strong>High-resolution, laboratory micro-computed tomography (micro-CT) was used to non-destructively image external and internal stent encrustation in four representative stents. X-ray diffractometry (XRD) and scanning electron microscopy-energy dispersive x-ray spectroscopy (SEM-EDS) enabled parallel analysis of mineral structure and chemical content of samples collected from external and internal encrusted material along the distal, proximal and mid-ureteral stent regions.</p><p><strong>Results: </strong>Extensive stent lumen encrustation can occur within any region of a stent, with only incidental or minor external encrustation, along the entire length of the stent. External and internal encrusted materials in a given stent are generally similar, consisting of a combination of amorphous (mostly organic) and crystalline mineral deposits.</p><p><strong>Conclusion: </strong>Micro-CT demonstrates that significant stent lumen encrustation can occur, which can lead to partial or full stent lumen occlusion, even when the exterior stent wall is essentially free of encrusted material.</p>","PeriodicalId":21008,"journal":{"name":"Research and Reports in Urology","volume":"14 1","pages":"159-166"},"PeriodicalIF":2.0,"publicationDate":"2022-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045707/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49442592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimal Delivery of Follow-Up Care for the Prevention of Stone Recurrence in Urolithiasis Patients: Improving Outcomes. 预防泌尿系结石患者结石复发的最佳随访护理:改善疗效
IF 2 Q2 UROLOGY & NEPHROLOGY Pub Date : 2022-04-19 eCollection Date: 2022-01-01 DOI: 10.2147/RRU.S277498
Lazaros Tzelves, Marinos Berdempes, Panagiotis Mourmouris, Iraklis Mitsogiannis, Andreas Skolarikos

Urolithiasis is a common clinical condition with frequent recurrences. Advances in knowledge of pathophysiological mechanisms permit the categorization of patients to low and high risk for recurrence, with specific metabolic abnormalities diagnosed in the second category. Follow-up is essential for patients with urolithiasis and consists of both imaging and metabolic follow-up with urine studies. No formal guidelines or solid evidence currently exists regarding frequency and type of follow-up studies to be performed in each category. This review aims to summarize existing evidence regarding follow-up, in order to guide clinicians on how and when to follow-up urolithiasis patients according to existing clinical scenario.

摘要泌尿系结石是一种常见的临床疾病,经常复发。病理生理机制知识的进步允许将患者分为复发的低风险和高风险,第二类诊断为特定的代谢异常。随访对尿石症患者至关重要,包括影像学和尿液代谢随访。目前还没有关于每一类随访研究的频率和类型的正式指南或确凿证据。本综述旨在总结有关随访的现有证据,以指导临床医生根据现有临床情况如何以及何时对尿石症患者进行随访。
{"title":"Optimal Delivery of Follow-Up Care for the Prevention of Stone Recurrence in Urolithiasis Patients: Improving Outcomes.","authors":"Lazaros Tzelves, Marinos Berdempes, Panagiotis Mourmouris, Iraklis Mitsogiannis, Andreas Skolarikos","doi":"10.2147/RRU.S277498","DOIUrl":"10.2147/RRU.S277498","url":null,"abstract":"<p><p>Urolithiasis is a common clinical condition with frequent recurrences. Advances in knowledge of pathophysiological mechanisms permit the categorization of patients to low and high risk for recurrence, with specific metabolic abnormalities diagnosed in the second category. Follow-up is essential for patients with urolithiasis and consists of both imaging and metabolic follow-up with urine studies. No formal guidelines or solid evidence currently exists regarding frequency and type of follow-up studies to be performed in each category. This review aims to summarize existing evidence regarding follow-up, in order to guide clinicians on how and when to follow-up urolithiasis patients according to existing clinical scenario.</p>","PeriodicalId":21008,"journal":{"name":"Research and Reports in Urology","volume":"14 1","pages":"141-148"},"PeriodicalIF":2.0,"publicationDate":"2022-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9034870/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46860360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Buccal Mucosal Ureteroplasty for the Management of Ureteral Strictures: Patient Selection and Considerations 尿道粘膜输尿管成形术治疗输尿管狭窄:患者的选择和考虑
IF 1.6 Q2 UROLOGY & NEPHROLOGY Pub Date : 2022-04-09 DOI: 10.2147/RRU.S291950
Ashley N. Gonzalez, Kirtishri Mishra, Lee Cheng Zhao
Abstract The landscape for upper genitourinary tract reconstruction continues to evolve with innovations in technology and surgical techniques. While the use of flaps and grafts in reconstructive surgery is not a novel concept, the application of buccal mucosal grafts in ureteral reconstruction has only been described over the last 20 years and is now an important adjunct for approaching ureteral strictures. Alongside the increasing use of robotics in urologic surgery, the options available for reconstruction of the upper tract with decreasing patient morbidity are multiplying. Herein, we aim to highlight various patient characteristics which may favor the use of buccal mucosa for addressing ureteral strictures.
随着技术和手术技术的创新,上生殖道重建的前景不断发展。虽然在输尿管重建手术中使用皮瓣和移植物并不是一个新概念,但在过去的20年里,颊粘膜移植物在输尿管重建中的应用才被描述出来,现在是输尿管狭窄治疗的重要辅助手段。随着机器人技术在泌尿外科手术中的应用越来越多,上尿路重建的选择也越来越多,同时降低了患者的发病率。在此,我们的目的是强调各种患者的特点,这些特点可能有利于使用颊粘膜治疗输尿管狭窄。
{"title":"Buccal Mucosal Ureteroplasty for the Management of Ureteral Strictures: Patient Selection and Considerations","authors":"Ashley N. Gonzalez, Kirtishri Mishra, Lee Cheng Zhao","doi":"10.2147/RRU.S291950","DOIUrl":"https://doi.org/10.2147/RRU.S291950","url":null,"abstract":"Abstract The landscape for upper genitourinary tract reconstruction continues to evolve with innovations in technology and surgical techniques. While the use of flaps and grafts in reconstructive surgery is not a novel concept, the application of buccal mucosal grafts in ureteral reconstruction has only been described over the last 20 years and is now an important adjunct for approaching ureteral strictures. Alongside the increasing use of robotics in urologic surgery, the options available for reconstruction of the upper tract with decreasing patient morbidity are multiplying. Herein, we aim to highlight various patient characteristics which may favor the use of buccal mucosa for addressing ureteral strictures.","PeriodicalId":21008,"journal":{"name":"Research and Reports in Urology","volume":"14 1","pages":"135 - 140"},"PeriodicalIF":1.6,"publicationDate":"2022-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41339433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Catheter-Associated Urinary Tract Infections: Current Challenges and Future Prospects. 导管相关性尿路感染:当前的挑战和未来的展望
IF 1.6 Q2 UROLOGY & NEPHROLOGY Pub Date : 2022-04-04 eCollection Date: 2022-01-01 DOI: 10.2147/RRU.S273663
Glenn T Werneburg

Catheter-associated urinary tract infection (CAUTI) is the most common healthcare-associated infection and cause of secondary bloodstream infections. Despite many advances in diagnosis, prevention and treatment, CAUTI remains a severe healthcare burden, and antibiotic resistance rates are alarmingly high. In this review, current CAUTI management paradigms and challenges are discussed, followed by future prospects as they relate to the diagnosis, prevention, and treatment. Clinical and translational evidence will be evaluated, as will key basic science studies that underlie preventive and therapeutic approaches. Novel diagnostic strategies and treatment decision aids under development will decrease the time to diagnosis and improve antibiotic accuracy and stewardship. These include several classes of biomarkers often coupled with artificial intelligence algorithms, cell-free DNA, and others. New preventive strategies including catheter coatings and materials, vaccination, and bacterial interference are being developed and investigated. The antibiotic pipeline remains insufficient, and new strategies for the identification of new classes of antibiotics, and rational design of small molecule inhibitor alternatives, are under development for CAUTI treatment.

摘要导管相关性尿路感染(CAUTI)是最常见的医疗相关感染,也是继发性血液感染的原因。尽管在诊断、预防和治疗方面取得了许多进展,但CAUTI仍然是一个严重的医疗负担,抗生素耐药性高得惊人。在这篇综述中,讨论了当前CAUTI管理模式和挑战,以及与诊断、预防和治疗相关的未来前景。将评估临床和转化证据,以及作为预防和治疗方法基础的关键基础科学研究。正在开发的新型诊断策略和治疗决策辅助工具将缩短诊断时间,提高抗生素的准确性和管理水平。其中包括几类生物标志物,通常与人工智能算法、无细胞DNA等相结合。正在开发和研究新的预防策略,包括导管涂层和材料、疫苗接种和细菌干扰。抗生素管道仍然不足,正在开发新的策略来识别新类别的抗生素,并合理设计小分子抑制剂替代品,用于治疗CAUTI。
{"title":"Catheter-Associated Urinary Tract Infections: Current Challenges and Future Prospects.","authors":"Glenn T Werneburg","doi":"10.2147/RRU.S273663","DOIUrl":"10.2147/RRU.S273663","url":null,"abstract":"<p><p>Catheter-associated urinary tract infection (CAUTI) is the most common healthcare-associated infection and cause of secondary bloodstream infections. Despite many advances in diagnosis, prevention and treatment, CAUTI remains a severe healthcare burden, and antibiotic resistance rates are alarmingly high. In this review, current CAUTI management paradigms and challenges are discussed, followed by future prospects as they relate to the diagnosis, prevention, and treatment. Clinical and translational evidence will be evaluated, as will key basic science studies that underlie preventive and therapeutic approaches. Novel diagnostic strategies and treatment decision aids under development will decrease the time to diagnosis and improve antibiotic accuracy and stewardship. These include several classes of biomarkers often coupled with artificial intelligence algorithms, cell-free DNA, and others. New preventive strategies including catheter coatings and materials, vaccination, and bacterial interference are being developed and investigated. The antibiotic pipeline remains insufficient, and new strategies for the identification of new classes of antibiotics, and rational design of small molecule inhibitor alternatives, are under development for CAUTI treatment.</p>","PeriodicalId":21008,"journal":{"name":"Research and Reports in Urology","volume":"14 1","pages":"109-133"},"PeriodicalIF":1.6,"publicationDate":"2022-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992741/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47486619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 27
Clinical Utility of β3-Adrenoreceptor Agonists for the Treatment of Overactive Bladder: A Review of the Evidence and Current Recommendations β3-肾上腺素受体激动剂治疗膀胱过动症的临床应用:证据综述和当前建议
IF 1.6 Q2 UROLOGY & NEPHROLOGY Pub Date : 2022-04-01 DOI: 10.2147/RRU.S309144
J. Krhut, B. Skugarevská, D. Míka, L. Lund, P. Zvára
Abstract This nonsystematic review provides a summary of current evidence on the use of β3-adrenoreceptor agonists (β3-ARAs) for the treatment for lower urinary tract symptoms. Soon after their discovery in 1989, β3-ARs were identified as a predominant adrenoreceptor subtype in the human urinary bladder. Although it is widely believed that β3-ARAs cause detrusor relaxation, the effect on bladder afferent signaling likely plays an important role in their mechanism of action as well. In 2011 and 2012, mirabegron was approved for clinical use in overactive bladder (OAB) patients. Pooled analysis of data from prospective randomized studies on >60,000 OAB patients showed that when compared to placebo, mirabegron was superior with respect to reducing the frequency, number, and severity of urgency episodes, number of incontinence episodes and increasing dry rate, but not in reduction of nocturia episodes. The only side effect showing significantly higher incidence than placebo was nasopharyngitis. Mirabegron is approved for OAB treatment in all age-groups and in pediatric patients with neurogenic bladder. Vibegron is another β3-ARA approved for OAB treatment in the US and Japan. Several large, multicenter, double-blind, randomized trials have documented statistically significant superiority of vibegron over placebo on all efficacy end points. Other β3-ARAs are being developed; however, to date none has been introduced to clinical use. All β3-ARAs provide efficacy similar to anticholinergics. They have a favorable safety profile and are well tolerated. Due to their different mechanisms of action, combination of β3-ARAs with anticholinergic compounds allows for increased efficacy.
本非系统综述综述了β3-肾上腺素受体激动剂(β3-ARAs)治疗下尿路症状的最新证据。在1989年被发现后不久,β3- ar被确定为人类膀胱中主要的肾上腺素受体亚型。虽然人们普遍认为β3-ARAs可引起逼尿肌舒张,但其作用机制中对膀胱传入信号的影响可能也起重要作用。2011年和2012年,mirabegron被批准用于膀胱过动症(OAB)患者的临床应用。对60000名OAB患者的前瞻性随机研究数据的汇总分析显示,与安慰剂相比,mirabegron在减少急症发作的频率、次数和严重程度、失禁发作次数和增加干率方面具有优势,但在减少夜尿发作方面没有优势。唯一明显高于安慰剂的副作用是鼻咽炎。Mirabegron被批准用于所有年龄组和小儿神经性膀胱患者的OAB治疗。Vibegron是美国和日本批准用于OAB治疗的另一种β3-ARA。几项大型、多中心、双盲、随机试验证明,在所有疗效终点上,vibegron都比安慰剂有统计学上的显著优势。其他β3- ara正在开发中;然而,到目前为止,还没有一种被引入临床应用。所有β3-ARAs均具有与抗胆碱能药相似的功效。它们具有良好的安全性和耐受性。由于它们的作用机制不同,β3-ARAs与抗胆碱能化合物的结合可以提高疗效。
{"title":"Clinical Utility of β3-Adrenoreceptor Agonists for the Treatment of Overactive Bladder: A Review of the Evidence and Current Recommendations","authors":"J. Krhut, B. Skugarevská, D. Míka, L. Lund, P. Zvára","doi":"10.2147/RRU.S309144","DOIUrl":"https://doi.org/10.2147/RRU.S309144","url":null,"abstract":"Abstract This nonsystematic review provides a summary of current evidence on the use of β3-adrenoreceptor agonists (β3-ARAs) for the treatment for lower urinary tract symptoms. Soon after their discovery in 1989, β3-ARs were identified as a predominant adrenoreceptor subtype in the human urinary bladder. Although it is widely believed that β3-ARAs cause detrusor relaxation, the effect on bladder afferent signaling likely plays an important role in their mechanism of action as well. In 2011 and 2012, mirabegron was approved for clinical use in overactive bladder (OAB) patients. Pooled analysis of data from prospective randomized studies on >60,000 OAB patients showed that when compared to placebo, mirabegron was superior with respect to reducing the frequency, number, and severity of urgency episodes, number of incontinence episodes and increasing dry rate, but not in reduction of nocturia episodes. The only side effect showing significantly higher incidence than placebo was nasopharyngitis. Mirabegron is approved for OAB treatment in all age-groups and in pediatric patients with neurogenic bladder. Vibegron is another β3-ARA approved for OAB treatment in the US and Japan. Several large, multicenter, double-blind, randomized trials have documented statistically significant superiority of vibegron over placebo on all efficacy end points. Other β3-ARAs are being developed; however, to date none has been introduced to clinical use. All β3-ARAs provide efficacy similar to anticholinergics. They have a favorable safety profile and are well tolerated. Due to their different mechanisms of action, combination of β3-ARAs with anticholinergic compounds allows for increased efficacy.","PeriodicalId":21008,"journal":{"name":"Research and Reports in Urology","volume":"14 1","pages":"167 - 175"},"PeriodicalIF":1.6,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47314651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Penile Vibratory Stimulation for Semen Retrieval in Men with Spinal Cord Injury: Patient Perspectives 阴茎振动刺激对脊髓损伤男性的精液回收:患者观点
IF 1.6 Q2 UROLOGY & NEPHROLOGY Pub Date : 2022-04-01 DOI: 10.2147/RRU.S278797
E. Ibrahim, N. Brackett, C. Lynne
Abstract Spinal cord injury (SCI) is a catastrophic event with sequelae that are not often apparent. For the spinal cord injured man, the inability to become a biologic father because of reproductive dysfunction becomes a major negative factor in his self-esteem and a hindrance to his social rehabilitation. Approximately, 90% of men with SCI develop ejaculatory dysfunction and only 10% can ejaculate by masturbation or during sexual activity. It is only over the last 40 years that it has been possible to properly study and understand the various factors contributing to the problem. Advances have been made in governmental and societal attitudes that have led to improvements in the treatment and rehabilitation of persons with SCI and other disabilities. It is now possible to retrieve sperm reliably and safely from men with SCI. Although their semen quality is often impaired, there is a very reasonable chance for achieving biologic fatherhood using assisted reproductive techniques. Penile vibratory stimulation (PVS) is a safe, reliable, efficient, and cost-effective, method of sperm retrieval that will produce an ejaculate in up to 86% of the patients with a level of injury T10 or rostral, which accounts for approximately 80% of the SCI population. Some motile sperm will be present in 90% of these ejaculates. In approximately 75% of the ejaculates, there will be greater than 5 million motile sperm, allowing a couple to explore all the options available to a couple seeking help in conceiving a child. The Male Fertility Program of the Miami Project to Cure Paralysis is at the leading edge of basic and clinical research contributing to the management of infertility in men with SCI. This review will outline “how we got there” enabling us to recommend PVS as the first choice in assisting men with SCI to become biologic parents.
摘要脊髓损伤是一种灾难性事件,其后遗症并不明显。对于脊髓损伤的男性来说,由于生殖功能障碍而无法成为亲生父亲,这成为他自尊的主要负面因素,也是他社会康复的障碍。大约90%的SCI男性出现射精功能障碍,只有10%的男性可以通过手淫或性活动射精。只有在过去的40年里,才有可能适当地研究和理解导致这个问题的各种因素。政府和社会态度取得了进展,改善了脊髓损伤和其他残疾人的治疗和康复。现在可以可靠、安全地从SCI患者身上取回精子。尽管他们的精液质量经常受损,但使用辅助生殖技术实现生物父亲身份的机会是非常合理的。阴茎振动刺激(PVS)是一种安全、可靠、高效且具有成本效益的精子回收方法,可在高达86%的T10或吻侧损伤患者中产生射精,约占SCI人群的80%。90%的精液中都会有一些能动的精子。在大约75%的射精中,会有超过500万个活动精子,这使得一对夫妇可以探索寻求帮助怀孕的夫妇的所有选择。迈阿密治疗瘫痪项目的男性生育计划在基础和临床研究中处于领先地位,有助于SCI男性不育的管理。这篇综述将概述“我们是如何做到这一点的”,使我们能够推荐PVS作为帮助SCI男性成为亲生父母的首选。
{"title":"Penile Vibratory Stimulation for Semen Retrieval in Men with Spinal Cord Injury: Patient Perspectives","authors":"E. Ibrahim, N. Brackett, C. Lynne","doi":"10.2147/RRU.S278797","DOIUrl":"https://doi.org/10.2147/RRU.S278797","url":null,"abstract":"Abstract Spinal cord injury (SCI) is a catastrophic event with sequelae that are not often apparent. For the spinal cord injured man, the inability to become a biologic father because of reproductive dysfunction becomes a major negative factor in his self-esteem and a hindrance to his social rehabilitation. Approximately, 90% of men with SCI develop ejaculatory dysfunction and only 10% can ejaculate by masturbation or during sexual activity. It is only over the last 40 years that it has been possible to properly study and understand the various factors contributing to the problem. Advances have been made in governmental and societal attitudes that have led to improvements in the treatment and rehabilitation of persons with SCI and other disabilities. It is now possible to retrieve sperm reliably and safely from men with SCI. Although their semen quality is often impaired, there is a very reasonable chance for achieving biologic fatherhood using assisted reproductive techniques. Penile vibratory stimulation (PVS) is a safe, reliable, efficient, and cost-effective, method of sperm retrieval that will produce an ejaculate in up to 86% of the patients with a level of injury T10 or rostral, which accounts for approximately 80% of the SCI population. Some motile sperm will be present in 90% of these ejaculates. In approximately 75% of the ejaculates, there will be greater than 5 million motile sperm, allowing a couple to explore all the options available to a couple seeking help in conceiving a child. The Male Fertility Program of the Miami Project to Cure Paralysis is at the leading edge of basic and clinical research contributing to the management of infertility in men with SCI. This review will outline “how we got there” enabling us to recommend PVS as the first choice in assisting men with SCI to become biologic parents.","PeriodicalId":21008,"journal":{"name":"Research and Reports in Urology","volume":"14 1","pages":"149 - 157"},"PeriodicalIF":1.6,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41492854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Research and Reports in Urology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1